Safety and efficacy of adjunctive intravenous tirofiban after successful endovascular thrombectomy in patients with large vessel occlusion stroke

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500106021

Enrollment

Unknown

Registered

2025-07-16

Start date

2025-07-20

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute stroke

Interventions

Experimental group:Patients in this group received antiplatelet therapy with tirofiban

Control group:Patients in this group did not receive intravenous tirofiban antiplatelet therapy

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Clinical Enrollment Criteria: (1) Age >=18 years old, pre-onset mRS score =80 years old, pre-onset mRS score =6 points; (4) Written informed consent signed by the patient or family member; 2. Image Enrollment Criteria: (1) CTA/MRA/DSA confirmed that the blood vessels responsible for the acute ischemic stroke were occlusion of the internal carotid artery, middle cerebral artery M1/M2, anterior cerebral artery A1 segment, or vertebrobasilar artery occlusion; (2) Baseline ASPECT score>=3 points; (3) Receiving endovascular therapy and achieving successful reperfusion (defined as Expanded TICI Rating Scale (eTICI) grade 2b and above).

Exclusion criteria

Exclusion criteria: 1. Cardiogenic embolism; 2. Intraoperative DSA imaging showed vascular dissection, vascular rupture, and contrast agent extravasation; 3. Routine platelet count less than 100×10^9/L; 4. Renal insufficiency, glomerular filtration rate < 60 mL/min; 5. Pregnant or lactating women; 6. Allergy to tirofiban, contrast media, nickel, titanium or its alloys; 7. Previous bleeding disorder, severe heart, liver or kidney disease, or sepsis; 8. Life expectancy of < 6 months due to any advanced disease; 9. Participating in other clinical trials; 10. Intracranial aneurysm and arteriovenous malformation with risk of bleeding; Brain tumors with a mass effect on imaging.

Design outcomes

Primary

Measure	Time frame
The sum (%) of the proportion of patients with a 90-day modified Rankin Scale (mRS) score of 0-2 and the proportion of patients who recovered to their pre-onset mRS score;	—

Secondary

Measure	Time frame
Proportion of early improvement in neurological function;90 days mRS rating;Success rate of CTA/MRA vascular recanalization within 48 hours after surgery;	—

Countries

China

Contacts

Public ContactLiChaoqun

Xihua County Peoples Hospital

568258977@qq.com+86 394 2326066

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026